Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy.
dc.contributor.author | Bowyer, S | |
dc.contributor.author | Prithviraj, P | |
dc.contributor.author | Lorigan, Paul C | |
dc.contributor.author | Larkin, J | |
dc.contributor.author | McArthur, G | |
dc.contributor.author | Atkinson, V | |
dc.contributor.author | Millward, M | |
dc.contributor.author | Khou, M | |
dc.contributor.author | Diem, S | |
dc.contributor.author | Ramanujam, S | |
dc.contributor.author | Kong, B | |
dc.contributor.author | Liniker, E | |
dc.contributor.author | Guminski, A | |
dc.contributor.author | Parente, P | |
dc.contributor.author | Andrews, M C | |
dc.contributor.author | Parakh, S | |
dc.contributor.author | Cebon, J | |
dc.contributor.author | Long, G | |
dc.contributor.author | Carlino, M | |
dc.contributor.author | Klein, O | |
dc.date.accessioned | 2016-05-25T15:29:09Z | en |
dc.date.available | 2016-05-25T15:29:09Z | en |
dc.date.issued | 2016-05-10 | en |
dc.identifier.citation | Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. 2016, 114 (10):1084-9 Br J Cancer | en |
dc.identifier.issn | 1532-1827 | en |
dc.identifier.pmid | 27124339 | en |
dc.identifier.doi | 10.1038/bjc.2016.107 | en |
dc.identifier.uri | http://hdl.handle.net/10541/610720 | en |
dc.description.abstract | Recent phase III clinical trials have established the superiority of the anti-PD-1 antibodies pembrolizumab and nivolumab over the anti-CTLA-4 antibody ipilimumab in the first-line treatment of patients with advanced melanoma. Ipilimumab will be considered for second-line treatment after the failure of anti-PD-1 therapy. | |
dc.language.iso | en | en |
dc.rights | Archived with thanks to British journal of cancer | en |
dc.title | Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. | en |
dc.type | Article | en |
dc.contributor.department | Rockingham General Hospital, Cooloongup, Western Australia, Australia | en |
dc.identifier.journal | British Journal of Cancer | en |
html.description.abstract | Recent phase III clinical trials have established the superiority of the anti-PD-1 antibodies pembrolizumab and nivolumab over the anti-CTLA-4 antibody ipilimumab in the first-line treatment of patients with advanced melanoma. Ipilimumab will be considered for second-line treatment after the failure of anti-PD-1 therapy. |